Additional evaluation of independent large-scale cancer datasets17, 18 revealed recurrent somatic mutations in B3GNT2, B4GALT2 and ST6GALNAC2, accounting for ~3% of CRC cases (Supplementary Table S6). This evidence concerns the gene B3GNT2 and cancer.